JIA with Polyarthritis (≥5 Joints): What to Do When Initial Biologic + DMARD Therapy Fails to Achieve Low Disease Activity

Clinical Scenario

This protocol applies to children with juvenile idiopathic arthritis (JIA) and non-systemic polyarthritis — five or more joints ever involved — who are not in low disease activity despite current biologic combination therapy. Systemic arthritis and sacroiliitis are excluded from this population.

Prior Treatment Line — Target Not Reached

The previous step added a biologic agent (a TNFi: etanercept, adalimumab, infliximab, or golimumab; or alternatively abatacept or tocilizumab) to a DMARD (methotrexate), with combination therapy preferred over biologic monotherapy. The goal of that line — low disease activity (clinical JADAS-10 ≤2.5) — was not achieved, triggering escalation to this protocol.

Next-Line Approach (Partial — Full Protocol Below)

The recommended step involves switching to a different class of biologic therapy, though an alternative path may be appropriate in a specific subset of patients. Which agent to choose, in which circumstance, and the full decision criteria are available in the complete protocol.

Treatment Target

Achieve low disease activity (clinical JADAS-10 ≤2.5).

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/acr.23870

This group includes children with JIA and polyarthritis (≥5 joints ever involved) and may include children from different ILAR JIA categories but excludes children with systemic arthritis or sacroiliitis.

In patients with JIA and polyarthritis and moderate or high disease activity receiving a first TNFi (with or without DMARD), switching to a non-TNFi biologic (tocilizumab or abatacept) is conditionally recommended over switching to a second TNFi.

A second TNFi may be appropriate for patients with good initial response to their first TNFi (i.e., secondary failure).

Good disease control, with therapeutic escalation to achieve low disease activity, was recommended.

View source ↗